Designer Diagnostics Begins Marketing First Ever Environmental Test Kit for the Detection of Nontuberculous Mycobacteria
February 25 2008 - 8:00AM
Business Wire
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis, has today
announced that its wholly-owned medical devices subsidiary,
Designer Diagnostics, has started marketing the first-ever
environmental test kit for the detection of Nontuberculous
Mycobacteria (NTM) in water and soil. �The primary goal of these
environmental test kits is to reduce the number of NTM infections
worldwide by preventing the public�s exposure to NTM and
determining the source of origin of NTM infections in patients,�
explained Neil Roth, President of Designer Diagnostics. �In order
to accomplish this goal, we believe that every municipality,
hospital and water treatment facility should have these test kits
on hand for periodic testing of the environment,� he added.
Nontuberculous Mycobacterium, also known as atypical Tuberculosis
(Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a
bacteria that is found in a multitude of environments - in the
soil, in some domestic and wild animals, and perhaps most
importantly, in water, including showers and hot tubs. One of the
most common forms of NTM infections found in humans is
Mycobacterium avium complex (MAC). This is a primary cause of
respiratory disease in humans and is a leading cause of death in
HIV/AIDS patients. In December, Nutra Pharma announced that it
expanded its licensing agreement with Ohio-based NanoLogix, Inc.
(PINK�SHEETS:NNLX) to include additional intellectual property for
the use of testing the environment for NTM. �All of us at NanoLogix
are excited that this beneficial technology is finally coming to
market,� said Bret Barnhizer, CEO of NanoLogix, Inc. �These test
kits will not only play an important role in reducing NTM
infections in developing nations, but will also assist in the
detection and prevention of NTM exposure and infection in the
United States and other developed countries,� he added. Recently,
distinguished NTM research scientist Dr. Rahul Narang used the
Designer Diagnostics environmental test kits to test soil and water
samples collected from the environment of patients with NTM
infections. This was the first time the technique was used in India
and the findings were presented in November at the 38th Union World
Conference on Lung Health in Cape Town, South Africa. About Nutra
Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company
specializing in the acquisition, licensing and commercialization of
pharmaceutical products and technologies for the management of
neurological disorders, cancer, autoimmune and infectious diseases.
Nutra Pharma Corp., through its subsidiaries, carries out basic
drug discovery research and clinical development and also seeks
strategic licensing partnerships to reduce the risks associated
with the drug development process. The Company's holding,
ReceptoPharm, Inc., is developing these technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The
Company's subsidiary, Designer Diagnostics, is engaged in the
research and development of diagnostic test kits designed to be
used for the rapid identification of infectious diseases such as
Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
Nutra Pharma continues to identify and acquire intellectual
property and companies in the biotechnology arena.
http://www.NutraPharma.com http://www.DesignerDiagnostics.com This
press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely
result," "are expected to," "will continue," "is anticipated,"
"estimate," "project," or similar expressions are intended to
identify "forward-looking statements." Actual results could differ
materially from those projected in Nutra Pharma's ("the Company")
business plan. The Company's business is subject to various risks,
which are discussed in the Company's filings with the Securities
and Exchange Commission ("SEC"). The marketing of Designer
Diagnostics� environmental test kits should not be construed as an
indication in any way whatsoever of the value of the Company or its
common stock. The Company's filings may be accessed at the SEC's
Edgar system at www.sec.gov. Statements made herein are as of the
date of this press release and should not be relied upon as of any
subsequent date. The Company cautions readers not to place reliance
on such statements. Unless otherwise required by applicable law, we
do not undertake, and we specifically disclaim any obligation, to
update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024